Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour By Ogkologos - March 18, 2026 130 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANEUVER study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Breast Cancer Survivor Given 12 Months to Live After Left Side... April 2, 2021 How Finding the Right Primary Care Physician During Cancer Has Helped... March 24, 2021 FDA Warns That Robotic Surgery May Lower Life Expectancy for Breast... March 1, 2019 How to Avoid Spreading Harmful Chemo Chemicals to Members of Your... August 4, 2021 Load more HOT NEWS FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations EMA Recommends Extension of Indications for Nivolumab Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated,...
